Development of high‑resolution melting analysis for ABCB1 promoter methylation: Clinical consequences in breast and ovarian carcinoma.

Autor:	Vaclavikova R; Toxicogenomics Unit, Centre of Toxicology and Health Safety, National Institute of Public Health, 10042 Prague, Czech Republic., Klajic J; Division of Medicine, Department of Clinical Molecular Biology and Laboratory Science (EpiGen), Akershus University Hospital, 1478 Lørenskog, Norway., Brynychova V; Toxicogenomics Unit, Centre of Toxicology and Health Safety, National Institute of Public Health, 10042 Prague, Czech Republic., Elsnerova K; Toxicogenomics Unit, Centre of Toxicology and Health Safety, National Institute of Public Health, 10042 Prague, Czech Republic., Alnaes GIG; Department of Genetics, Institute for Cancer Research, Rikshospitalet‑Radiumhospital Medical Center, 0372 Oslo, Norway., Tost J; Laboratory for Epigenetics and Environment, Centre National de Génotypage, CEA‑Institut de Génomique, 91057 Evry, France., Kristensen VN; Division of Medicine, Department of Clinical Molecular Biology and Laboratory Science (EpiGen), Akershus University Hospital, 1478 Lørenskog, Norway., Rob L; Department of Gynecology and Obstetrics, Third Faculty of Medicine and Vinohrady University Hospital, Charles University, 10034 Prague., Kodet R; Department of Pathology and Molecular Medicine, Second Faculty of Medicine and Motol University Hospital, Charles University in Prague, 15006 Prague, Czech Republic., Skapa P; Department of Pathology and Molecular Medicine, Second Faculty of Medicine and Motol University Hospital, Charles University in Prague, 15006 Prague, Czech Republic., Mrhalova M; Department of Pathology and Molecular Medicine, Second Faculty of Medicine and Motol University Hospital, Charles University in Prague, 15006 Prague, Czech Republic., Soucek P; Toxicogenomics Unit, Centre of Toxicology and Health Safety, National Institute of Public Health, 10042 Prague, Czech Republic.
Jazyk:	angličtina
Zdroj:	Oncology reports [Oncol Rep] 2019 Aug; Vol. 42 (2), pp. 763-774. Date of Electronic Publication: 2019 Jun 05.
DOI:	10.3892/or.2019.7186
Abstrakt:	Multidrug resistance to anticancer drugs, which is often associated with enhanced expression of the ATP‑binding cassette (ABC) transporter P‑glycoprotein (encoded by the ABCB1 gene) may limit the effects of cancer therapy. Epigenetic regulation of ABCB1 expression may thus have a clinical impact. A detailed assessment of ABCB1 promoter methylation is of importance for predicting therapy outcome and prognosis. Thus, validated methods for the analysis of ABCB1 promoter methylation are urgently required. In the present study, high‑resolution melting (HRM) analysis of the CpG island regions covering the distal promoter of the ABCB1 gene was developed and compared with pyrosequencing. In addition, the clinical effects of the methylation status of the ABCB1 promoter were analyzed in patients with breast and ovarian carcinoma prior and subsequent to chemotherapy treatment. HRM analysis of ABCB1 methylation correlated with the results of pyrosequencing (P=0.001) demonstrating its analytical validity and utility. Hypermethylation of the analyzed ABCB1 promoter region was significantly correlated with low levels of the ABCB1 transcript in tumors from a subset of patients with breast and ovarian carcinoma prior to chemotherapy but not following treatment. Finally, high ABCB1 transcript levels were observed in tumors of patients with short progression‑free survival prior to chemotherapy. Our data suggest the existence of functional epigenetic changes in the ABCB1 gene with prognostic value in tumor tissues of patients with breast and ovarian carcinoma. The clinical importance of such changes should be further evaluated.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu